GAL-7-specific nanobodies for treatment of triple-negative breast cancer

GAL-7特异性纳米抗体用于治疗三阴性乳腺癌

• 批准号: 388794
• 负责人: St-Pierre Yves
• 金额: $ 27.03万
• 依托单位: INRS-Institut Armand-Frappier (Laval)
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2018
• 资助国家: 加拿大
• 起止时间: 2018-09-01 至 2021-09-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=388794&lang=en
• 关键词: Galectins

The immune system plays a key role in fighting cancer. Unfortunately, cancer cells release a number of factors that neutralize the activity of cancer-killing immune cells. Galectin-7 is a small protein that is produced and released at abnormally high leve

免疫系统在对抗癌症中起着关键作用。不幸的是，癌细胞会释放一些因子来中和杀死癌症的免疫细胞的活性。半乳糖凝集素-7是一种小的蛋白质，产生和释放在异常高的水平